OpenOutcrier
Posted - 2 weeks ago
$MOLN (+16.8% pre) Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going https://ooc.bz/l/46601
briefingcom
Posted - 10/22/24
Gapping up: $IRTC +12.3% $MLI +10.2% $MMM +6% $FLXS +5.9% $MOLN +5.1%
DonCorleone77
Posted - 10/22/24
$MOLN $NVS Molecular Partners, Orano Med announce presentation of MP0712 data Molecular Partners (MOLN) and Orano Med announced the oral presentation of the latest preclinical data supporting MP0712 as a Radio-DARPin Therapeutic, or RDT, at the European Assocation of Nuclear Medicine, or EANM, Congress which runs October 19-23 in Hamburg, Germany. MP0712 is a co-developed 212Pb-labeled RDT candidate targeting delta-like ligand 3, or DLL3. Molecular Partners and Orano Med anticipate initiating first-in-human studies, pending regulatory clearance, in 2025. Initial clinical data of MP0712 is also anticipated in 2025. The presentation highlights that attractive tumor to kidney, or T:K, ratios of greater than can be achieved in biodistribution studies across several models, including in a disseminated tumor model with clinically relevant DLL3 expression levels. This suggests strong uptake by the targeted tissue while minimally impacting healthy tissues. In addition, in vivo data indicated that tumor uptake was specific to DLL3. Dose-range finding studies in mice confirmed that treatment at a clinically relevant dosage was well tolerated, supporting a favorable safety profile. Finally, MP0712 led to strong and dose-dependent efficacy in mice bearing established tumors with clinically-relevant levels of DLL3 expression and at a clinically-relevant dose, as compared to a positive control of a radiolabelled anti-DLL3 antibody rovalpituzumab. DLL3 is a highly relevant target for radiopharmaceutical therapy due to its abundant expression in tumors of patients with small cell lung cancer and other aggressive neuroendocrine tumors, while expression in healthy tissues is low. MP0712 has picomolar affinity and high specificity to human DLL3. Molecular Partners is developing its RDT platform for targeted delivery of radioactive payloads to solid tumors. Due to their small size, high specificity and affinity, DARPins are well-suited as potential vectors for efficient delivery of therapeutic radionuclides. DARPins are also readily designed as multispecifics, making bi-specific candidates a promising area of growth for Molecular Partner's RDT portfolio as additional targeting may help address target heterogeneity in many tumors. The portfolio includes programs being developed in-house as well as via collaborations with Orano Med and Novartis (NVS).
PenkeTrading
Posted - 10/22/24
I found you an Overbought RSI (Relative Strength Index) on the daily chart of Molecular Partners AG ADR. Is that bullish or bearish? $MOLN #RsiOverbought #NASDAQ
topstockalerts
Posted - 4 weeks ago
Top Movers pt2
$JCSE $MOLN $NCI $PHUN $SAVEQ
RallyRaider
Posted - 1 month ago
$MOLN what a chart.... anyone has a clue on where this is headed and why?
stockmet
Posted - 1 month ago
$MOLN demand zone 📈
topstockalerts
Posted - 1 month ago
Pre Market Top Gainers PT2 $SAVEQ $VSEE $GNPX $MOLN $LGMK
topstockalerts
Posted - 1 month ago
Pre Market Top Gainers PT2 $SAVEQ $VSEE $GNPX $MOLN $LGMK
LewisDaKat
Posted - 09/27/24
News Article $MOLN Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024 https://marketwirenews.com/news-releases/molecular-partners-announces-upcoming-top-rated-oral-8754300852558470.html $MOLN
themacromindset
Posted - 09/27/24
$MOLN $MOLN Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024
HaltTradeAlert
Posted - 2 months ago
$MOLN Halt Time: 09:36:52 Issue Symbol: MOLN Reason Code: LUDP Last Price: $5.74 Volume: 2.4 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
Avanzas
Posted - 2 months ago
$BCDA FDA approval also check Short Borrow Fee 😱 hope you join the train will hit hard $SIFY $AMC $MOLN $SGRP
Avanzas
Posted - 2 months ago
$BCDA FDA approval check out Borrow Free 😱😱
$AMC $GME $SIFY $MOLN
Avanzas
Posted - 2 months ago
$BCDA Starting to get expensive to short BCDA check out Borrow Free Rate 😱😱
$BNRG $ATPC $AMC $MOLN
Stock_Titan
Posted - 08/26/24
$MOLN Molecular Partners Reports H1 2024 Corporate Highlights and Financials
https://www.stocktitan.net/news/MOLN/molecular-partners-reports-h1-2024-corporate-highlights-and-quefdpz9j0ik.html
RallyRaider
Posted - 08/26/24
$MOLN Lets see 7.50 and we will see another 52w high
ChartLaboratory_com
Posted - 3 months ago
$IMNN $BBLG $MOLN $IVP $BBLG forming a cup, could be a strong move at open to $4.50+ bullish
ChartLaboratory_com
Posted - 3 months ago
$IMNN $BBLG $MOLN $IVP $BBLG +70% on fire wave 5 complete, lets look for consolidation at $3.00 / 2.60 and a later move in the day/ tomorrow. ChartLAb, LABALERTS, a one-stop shop for win-win trades and strategies. $2.60 support / $3.30 resist , $4.35 and $5.50 targets ChartLAB Daily: Join over 10,000 subscribers and get our best trade plans, exclusive news, and analysis of actionable trades every day. www.patreon.com/chartlab www.patreon.com/chartlab Sign In | Subscribe Subscribe to our newsletter and gain unlimited access to trusted and exclusive premium member benefits. Comments Join the conversation and share your thoughts on this analysis. #StocksToBuy #TradingTips #trading #stockmarket #stocks #alerts #swingtrade **Disclaimer:** This article is for informational purposes only and should not be considered as financial advice. Always consult with a financial advisor before making investment decisions.
ChartLaboratory_com
Posted - 3 months ago
$BBLG $IMNN $IVP $MOLN ChartLAB daily, day & swing trade watchlist + strategies. $MOLN Day Trade: Look for an entry around $8.30-$8.40 with a target of $9.00-$9.20. Swing Trade: Consider entering if it stabilizes above $8.58 with a target near the Bollinger Upper Band ($10.35). ChartLAB Daily: Join over 10,000 subscribers and get our best trade plans, exclusive news, and analysis of actionable trades every day. www.patreon.com/chartlab www.patreon.com/chartlab Sign In | Subscribe Subscribe to our newsletter and gain unlimited access to trusted and exclusive premium member benefits. Comments Join the conversation and share your thoughts on this analysis. #StocksToBuy #TradingTips #trading #stockmarket #stocks #alerts #swingtrade **Disclaimer:** This article is for informational purposes only and should not be considered as financial advice. Always consult with a financial advisor before making investment decisions.
Jompa89
Posted - 3 months ago
$MOLN
Alejos11
Posted - 07/31/24
$MOLN
tradingtwenty
Posted - 07/31/24
Top 5 stock gainers today that have trended in the past 24 hours: $NCNC 87.58% 🔥 $NUZE 61.62% $WINT 60.56% $POWL 37.81% $MOLN 36.84% Link: https://tradingtwenty.com/dashboard/trending/past
Jompa89
Posted - 07/31/24
$MOLN
Jompa89
Posted - 07/31/24
$MOLN can we reach 15 tomorrow ?
